



Financial Results (Consolidated) for the Nine Months Ended December 31, 2022

FUJIFILM Holdings Corporation

Teiichi Goto

President and Chief Executive Officer

Projected date of Quarterly report: February 14, 2023

Projected date of the beginning of cash dividends: —

Reference materials regarding operating results of the current quarter to be prepared: Yes

Meeting to explain operating results of the current quarter to be held: Yes

(Consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.)

February 8, 2023

URL: <https://holdings.fujifilm.com/en>

1. Results of the Nine Months Ended December 31, 2022 (From April 1, 2022 to December 31, 2022)

(1) OPERATING RESULTS

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

%; Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings	
		%		%		%		%
Nine months ended Dec. 31, 2022	2,094,260	12.5	202,637	8.7	204,787	(1.2)	153,735	(2.1)
Nine months ended Dec. 31, 2021	1,860,902	18.3	186,453	54.8	207,240	18.5	157,106	24.2

Note: Comprehensive income

Nine months ended December 31, 2022 ¥ 217,351 million (7.6%)

Nine months ended December 31, 2021 ¥ 202,032 million (34.8%)

	Net income attributable to FUJIFILM Holdings per share	Net income attributable to FUJIFILM Holdings per share (Assuming full dilution)
	Yen	Yen
Nine months ended Dec. 31, 2022	383.43	382.85
Nine months ended Dec. 31, 2021	392.40	391.46

(2) FINANCIAL POSITION

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

	Total assets	Total equity (Net asset)	FUJIFILM Holdings shareholders' equity	FUJIFILM Holdings shareholders' equity ratio to total assets
				%
As of Dec. 31, 2022	4,148,528	2,718,943	2,694,831	65.0
As of March 31, 2022	3,955,280	2,524,940	2,502,657	63.3

2. Cash Dividends

	Cash dividends per share				
	1st Quarter	2nd Quarter	3rd Quarter	Year End	Year Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2022	-	55.00	-	55.00	110.00
Year ending March 31, 2023	-	60.00			
Year ending March 31, 2023 (Forecast)				60.00	120.00

Note: Changes in dividends forecast during the quarter under review: None

3. Forecast for the Fiscal Year Ending March 31, 2023 (From April 1, 2022 to March 31, 2023)

Amount Unit: Millions of yen unless otherwise specified / Figures are rounded off to the nearest million yen

%; Changes from the corresponding period of the previous fiscal year

	Revenue		Operating income		Income before income taxes		Net income attributable to FUJIFILM Holdings		Net income attributable to FUJIFILM Holdings per share	
		%		%		%		%		Yen
For the Year ending March 31, 2023	2,800,000	10.9	260,000	13.2	270,000	3.7	200,000	(5.3)		498.64

Note: Changes in forecast which was recently announced: None

Note: Net income attributable to FUJIFILM Holdings per share is calculated using the number of shares issued as of December 31, 2022 excluding treasury shares for the average number of shares for the relevant period.

Notes

(1) Changes in status of material subsidiaries during this quarter

(Company newly consolidated or removed from consolidation): None

(2) Adoption of simplified method of accounting or specific accounting treatments: None

(3) Changes in accounting principles

1. Changes in accounting policies accompanied by revisions of accounting standards: None

2. Changes in accounting policies other than 1. above: None

(4) Number of shares outstanding

1. Issued (including treasury stock):

2. Treasury stock:

3. Average number of shares:

As of Dec. 31, 2022	514,625,728	As of March 31, 2022	514,625,728
As of Dec. 31, 2022	113,535,858	As of March 31, 2022	113,834,546
Nine months ended Dec. 31, 2022	400,752,991	Nine months ended Dec. 31, 2021	400,302,640

This report is not reviewed.

Explanation of Appropriate Use of Forecast and Other Special Items

Statements regarding future events including forecasts of operating results are based on limited available information and reasonable assumptions as of today. The Company does not have an intention of guaranteeing the realization of the forecasts. Actual operating results are always subject to change significantly due to various matters. Assumptions for the forecasts and warnings for users of the forecasts are mentioned in the page 6, (3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results in 1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER.

[INDEX]

1.	QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER	P.2
(1)	Explanation on Consolidated Operating Results	P.2
(2)	Explanation on the Consolidated Financial Position	P.6
(3)	Explanation on Projected Information on Forecasts of the Consolidated Operating Results	P.6
2.	MATTERS RELATING TO SUMMARY (OTHER) INFORMATION	P.6
(1)	Changes in Status of Material Subsidiaries during This Quarter	P.6
(2)	Adoption of Simplified Method of Accounting or Specific Accounting Treatments:	P.7
(3)	Changes in Accounting Principles:	P.7
3.	OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION:	P.7
4.	CONSOLIDATED FINANCIAL STATEMENTS	P.8
(1)	Consolidated Balance Sheets	P.8
(2)	Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	P.10
	(Consolidated Statements of Income)	P.10
	Nine months ended December 31	P.10
	Three months ended December 31	P.11
	(Consolidated Statements of Comprehensive Income)	P.12
	Nine months ended December 31	P.12
	Three months ended December 31	P.12
(3)	Consolidated Statements of Cash Flows	P.13
(4)	Notes to Consolidated Financial Statements	P.14
	(Notes Relating to the Going Concern Assumption)	P.14
	(Segment Information)	P.14
	1) Nine months ended December 31	P.14
	2) Three months ended December 31	P.15
	(Notes on Significant Changes to FUJIFILM Holdings Shareholders' Equity)	P.15
	(Subsequent Event)	P.16

1. QUALITATIVE INFORMATION ON OPERATING RESULTS DURING THE CURRENT QUARTER

(1) Explanation on Consolidated Operating Results

Amount Unit: Billions of yen

	Nine months ended December 31, 2022		Nine months ended December 31, 2021		Change (Amount)	Change (%)
Domestic revenue	34.5%	722.8	38.2%	710.4	12.4	1.7%
Overseas revenue	65.5%	1,371.5	61.8%	1,150.5	221.0	19.2%
Revenue	100.0%	2,094.3	100.0%	1,860.9	233.4	12.5%
Operating income	9.7%	202.6	10.0%	186.5	16.1	8.7%
Income before income taxes	9.8%	204.8	11.1%	207.2	(2.4)	(1.2%)
Net income attributable to FUJIFILM Holdings	7.3%	153.7	8.4%	157.1	(3.4)	(2.1%)
Exchange rates (Yen / US\$)		¥137		¥111	¥26	
Exchange rates (Yen / Euro)		¥141		¥131	¥10	

In the nine months ended December 31, 2022, the Fujifilm Group recorded ¥2,094.3 billion in consolidated revenue (up 12.5% year-over-year), reflecting sales increases mainly in the medical systems, the electronic materials and the imaging.

Operating income increased to ¥202.6 billion (up 8.7% year-over-year). Consolidated income before income taxes amounted to ¥204.8 billion (down 1.2% year-over-year), reflecting such factors as a decrease in valuation gains on marketable and investment securities, and consolidated net income attributable to FUJIFILM Holdings totaled ¥153.7 billion (down 2.1% year-over-year). The effective currency exchange rates for the U.S. dollar and the euro against the yen during the nine months were ¥137 and ¥141, respectively.

Revenue by Operating Segment

Amount Unit: Billions of yen

Segment	Nine months ended December 31, 2022	Nine months ended December 31, 2021	Change (Amount)	Change (%)
Healthcare	633.8	576.7	57.1	9.9%
Materials	522.7	467.3	55.4	11.8%
Business Innovation	614.1	556.7	57.4	10.3%
Imaging	323.7	260.2	63.5	24.4%
Consolidated Total	2,094.3	1,860.9	233.4	12.5%

Operating Income by Operating Segment

Amount Unit: Billions of yen

Segment	Nine months ended December 31, 2022	Nine months ended December 31, 2021	Change (Amount)	Change (%)
Healthcare	60.6	75.3	(14.7)	(19.5%)
Materials	59.5	58.2	1.3	2.3%
Business Innovation	47.8	41.9	5.9	14.2%
Imaging	62.7	34.7	28.0	80.8%
Corporate Expenses and Eliminations	(28.0)	(23.6)	(4.4)	—
Consolidated Total	202.6	186.5	16.1	8.7%

*Since the first half of the fiscal year ending March 31, 2023, revenue and operating income from the professional-use multifunction device business have been reclassified from the Business Innovation segment to the Materials segment.

Figures for the first nine months of the previous consolidated fiscal year are based on the segment classification after the above changes.

Healthcare Segment

In the Healthcare segment, consolidated revenue amounted to ¥633.8 billion (up 9.9% year-over-year).

Consolidated operating income amounted to ¥60.6 billion (down 19.5% year-over-year).

In the medical systems business, revenue soared due to steady sales mainly in the endoscopes, medical IT and ultrasound diagnostics fields. In the X-ray imaging diagnostics field, growing sales of the digital mammography system *AMULET Innovality* mainly in Europe, Southeast Asia and South/Central America, and strong sales of the X-ray equipment *FDR Smart X* and the mobile X-ray equipment *FDR Go Plus* mainly in Europe drove revenue higher. In the medical IT field, revenue surged due to higher sales of systems and services, in particular the Picture Archiving and Communication System (PACS) *SYNAPSE* and the 3D image analysis system *SYNAPSE VINCENT*, mainly in the U.S and Japan. In December 2022, we announced the acquisition of the digital pathology business of Inspirata, Inc. (based in the U.S.), which develops and sells digital pathology software for use in diagnosis. We will support improving efficiency of pathology diagnosis workflow by combining our PACS, which holds the world's top market share, with the digital pathology software to allow centralized management of in-hospital examination images. In the ultrasound diagnostics field, sales of the new stationary ultrasound diagnostic devices *ARIETTA 850DI* and *ARIETTA 650DI* rose mainly in Japan and Europe, in addition to steady sales of the *Sonosite PX* and other ultrasound diagnostic devices for point-of-care (POC) use mainly in the U.S. In the endoscopes field, revenue surged due to higher sales of products such as the *7000 System*, which includes image emphasis features such as LCI (Linked Color Imaging) that support endoscope observations by emphasizing slight differences in color of mucous membrane, mainly in Europe. In the In-Vitro Diagnostics (IVD) field, sales of the *FUJI DRI-CHEM* (blood biochemical test) equipment/slides and FUJIFILM Wako Pure Chemical Corporation's biochemical reagents and immunity-related testing equipment remained firm. In addition, sales of COVID-19 related testing equipment and reagents rose due to the spread of the COVID-19 pandemic in Japan. In the CT/MRI field, revenue rose because of a recovery trend from the effects of semiconductor and other component shortages, in addition to strong sales of new products, such as the *Supria Optica* whole-body X-ray CT diagnostic system in Japan and the *OASIS Velocity* superconducting open MRI in North America.

In the bio CDMO business, favorable progress in contract process development and contract manufacturing of biopharmaceuticals at the Denmark site, in addition to such factors as the impact of exchange rates, drove revenue higher. In June 2022, we announced the investment totaling 200 billion yen in large-scale facility expansion at the Denmark site to meet strong contract manufacturing needs for antibody drugs, and in the introduction of GMP production facilities, which is a commercial continuous production system capable of comprehensive manufacturing of active pharmaceutical ingredients from culture to purification, at the Texas site in the U.S. We will meet the needs for contract development of manufacturing process, small- to large-scale production, and contract manufacturing covering substances to drug formulation / packaging, targeting a wide range of biopharmaceuticals. We will also aim to become the best partner in the biopharmaceutical industry by providing new values to pharmaceutical companies through contract manufacturing based on the continuous production method, in addition to the batch production method.

In the life sciences business, overall revenue rose mainly due to the impact of exchange rates as well as higher year-over-year sales of reagents and cells while demand for cell culture media for COVID-19 vaccines/drugs ran its course.

In November 2022, we announced the establishment of a cell culture media manufacturing facility in North Carolina in the U.S. The global market for cell culture media is expanding in line with growing demand for antibody drugs and development of advanced therapies including cell therapy and gene therapy. We will provide strong support for R&D and manufacturing of biopharmaceuticals through our global manufacturing structure based in Europe, the U.S. and Japan.

In the pharmaceutical business, revenue fell mainly due to the transfer of FUJIFILM Toyama Chemical Co.,

Ltd.'s radiopharmaceutical business to PeptiDream Inc. in March 2022. In October 2022, we announced the introduction of a dual-use facility, which will be operated by FUJIFILM Toyama Chemical Co., Ltd. and is capable of manufacturing biopharmaceuticals during normal times and switching to vaccine production during a pandemic. By providing biopharmaceutical contract process development/manufacturing services to pharmaceutical companies, we will support prompt development and supply of vaccines domestically produced by these companies in the event of a pandemic.

In the consumer healthcare business, overall revenue was driven lower by such factors as a drop in sales of supplements compared to the same period last year, when there was a steady demand for dieting. In December 2022, we announced the March 2023 launch of *ASTALIFT THE SERUM BRIGHTENING* (quasi-drug), a medicated blemish-preventing serum that prevents irritation damage and fundamentally inhibits the development of blemishes, from the highly functional serum *ASTALIFT THE SERUM* series that applies our proprietary liposome technology to the cosmetic field. We will continue to provide unique products that cater to customer needs and contribute to people's beauty and health.

Materials Segment

In the Materials segment, consolidated revenue amounted to ¥522.7 billion (up 11.8% year-over-year).

Consolidated operating income amounted to ¥59.5 billion (up 2.3% year-over-year).

In the electronic materials business, revenue soared as sales of Chemical Mechanical Planarization (CMP) slurries continued to fare well as in the previous year and demand for polyimides, etc., whose applications expanded in the back-end processes, was brisk. We will continue to accelerate growth through stable supply of a wide range of products for cutting-edge semiconductors, demand for which is growing in line with the development of 5G and self-driving cars. In September 2022, we announced the construction of our first domestic CMP slurry manufacturing facility in Kumamoto, and in December, we announced the new construction of a manufacturing facility for color filter materials for image sensors in South Korea. Under our global manufacturing structure, we will further expand our business through stable production/supply of materials with high quality standards and by accelerating the market launch of new products that meet customer needs.

In the display materials business, revenue declined, hit by a reactionary drop in demand for monitors, tablets and TVs, which had increased in the previous year due to the COVID-19 pandemic, and the impact of production adjustments across the entire supply chain.

In the industrial products business, revenue climbed, driven by the impact of exchange rates as well as steady growth in sales of non-destructive inspection equipment/materials to the oil and gas industry. In the fine chemicals business, higher sales of polymerization materials and other chemical products drove revenue higher. In the recording media business, revenue decreased, hit by sluggish demand for data archiving tapes as major IT companies curtailed investments in data center construction amid the emerging risk of a global recession.

In the graphic communication business, the printing plate material field boosted revenue on contribution from sales price revisions in each region, despite the demand stagnation for offset printing in some regions resulting from soaring material and energy costs. In the digital printing field, revenue was driven higher by growth in shipments of production printers to the U.S. and Europe as market conditions recovered.

In the inkjet business, overall revenue climbed as sales of industrial inkjet printheads were strong due to growing demand in the European markets for building material printing and textiles, and ink sales, mainly dye inks for the household and office markets, also rose.

Business Innovation Segment

In the Business Innovation segment, consolidated revenue amounted to ¥614.1 billion (up 10.3% year-over-year).

Consolidated operating income amounted to ¥47.8 billion (up 14.2% year-over-year).

In the office solutions business, despite the impact of the COVID-19 lockdown in China, revenue was boosted by such factors as higher sales of multi-function devices/printers and consumables in Japan as well as increased exports to the U.S. and Europe, an upturn in sales of consumables in Southeast Asia, and the impact of exchange rates. In October 2022, as new products in the *ApeosPrint* Series, we launched flagship models *ApeosPrint C5570 / C4570*, A3-format color printers that support a wide variety of paper output and offer enhanced security. In December, we launched three models of A3-format monochrome printers, *ApeosPrint 4560 S*, *ApeosPrint 3960 S* and *ApeosPrint 3360 S*, which are the smallest and lightest in their class* and enable high-speed printing. They use *Super EA-Eco toner* that fuses at a low temperature, and reduce environmental impact during use through improved energy efficiency. We plan to further reinforce marketing of multi-function devices/printers to respond promptly to customer needs and enhance profitability. In the overseas market, we plan to pursue proactive business expansions, including OEM supply partnerships, by building product strategies tailored to the needs of each region and ensuring competitive advantages.

In the business solutions business, despite a reactionary decline after special demand from Japanese municipal governments in response to legal revisions in the previous fiscal year, revenue increased mainly due to an increase in sales of other solutions and services in Japan, growth in our overseas business process outsourcing (BPO) business, and the impact of exchange rates. In May 2022, we launched the *Bridge DX Library*, new solutions that strongly support customers in resolving DX issues on a business / operation basis and accelerates DX for small and midsize companies in Japan. The lineup increased to a total of 103 solutions in July 2022. In addition, as part of DX support for municipalities, in November 2022, we established a study working group with municipalities and corporations for digitalizing the copy request process of residence certificates from corporations to municipalities. The working group, led by FUJIFILM System Services Corp., a Fujifilm Group company, is comprised of ten municipalities and seven corporations. We will expand the business solutions business as the segment's core business by accelerating overseas development and offering solutions/services that support customers' DX.

*In volume and weight of the *ApeosPrint 3960 S* and *ApeosPrint 3360 S*, A3-format monochrome printer models with a monochrome continuous print speed of 30 or more sheets per minute (A4-format, single-sided). Weight does not include consumables. (As of October 2022, according to a survey by FUJIFILM Business Innovation Corp.)

Imaging Segment

In the Imaging segment, consolidated revenue amounted to ¥323.7 billion (up 24.4% year-over-year).

Consolidated operating income amounted to ¥62.7 billion (up 80.8% year-over-year).

In the consumer imaging field, steady sales of instant photo systems, color paper and dry minilabs / materials drove revenue higher. Revenue from instant photo systems was higher year-over-year as sales of both devices and film were strong. In November 2022, we launched the smartphone printer *INSTAX SQUARE Link*. It is rated highly in the market for its new functions: *AR Print* which allows users to apply an augmented reality (AR) effect to *INSTAX* prints, and *INSTAX Connect* which allows users to add chat messages to *INSTAX* images before sending them to any of their contacts, no matter how far apart you are. The *INSTAX Series* will continue to provide new values to people around the world by combining analog and digital technologies.

In the professional imaging field, revenue increased as sales of digital cameras fared well. In November 2022, we launched the mirrorless digital camera *FUJIFILM X-T5* as the latest and evolutionary model of the *X Series*, known for their compact and lightweight body and superior image quality based on our proprietary color reproduction technology, and further expanded our extensive lineup. To add to our lineup of cinema and broadcast lenses, in October 2022, we announced the development of *FUJINON HZK25-1000mm*, which is a box-type dual-format broadcast zoom lens supporting two types of large image sensors and achieves optical

performance exceeding 4K. It facilitates the use of cinema cameras, which is becoming increasingly common in the broadcast industry, offering cinematic visual depictions such as shallow depth-of-field for beautiful bokeh in live coverage of sporting events and music concerts. We will continue to develop and supply high-performance cameras, lenses and accessories to cater to the diversifying needs of frontline video professionals.

(2) Explanation on the Consolidated Financial Position

At the end of the third quarter of the fiscal year ending March 31, 2023, total assets increased by ¥193.2 billion compared with the end of the previous fiscal year (March 31, 2022) to ¥4,148.5 billion, mainly due to increases in inventories and property, plant and equipment. Total liabilities decreased by ¥0.8 billion to ¥1,429.6 billion. FUJIFILM Holdings shareholders' equity increased by ¥192.1 billion to ¥2,694.8 billion. As a result, the current ratio increased by 13.2 percentage points to 189.3%, the debt-equity ratio decreased by 4.2 percentage points to 53.0%, and the shareholders' equity ratio increased by 1.7 percentage points to 65.0% compared with the end of the previous fiscal year. The Company is maintaining a stable level of asset liquidity and a sound capital structure.

(Cash Flows)

Amount Unit: Billions of yen			
	Nine months ended December 31, 2022	Nine months ended December 31, 2021	Change
Net cash provided by operating activities	63.2	213.5	(150.3)
Net cash used in investing activities	(226.0)	(115.2)	(110.8)
Net cash used in financing activities	(21.3)	(77.9)	56.6

During the nine months of the fiscal year ending March 31, 2023, net cash provided by operating activities fell year-over-year by ¥150.3 billion to ¥63.2 billion mainly due to an increase in lease receivables. Net cash used in investing activities amounted to ¥226.0 billion due to the acquisition of property, plants, equipment, and other factors. Thus, free cash flow, or the sum of cash flows from operating and investing activities, amounted to ¥162.8 billion. Net cash used in financing activities amounted to ¥21.3 billion, due to payment of dividends and other factors.

As a result, cash and cash equivalents at the end of the quarter under review amounted to ¥317.8 billion, down ¥168.5 billion from the end of the previous fiscal year (March 31, 2022).

(3) Explanation on Projected Information on Forecasts of the Consolidated Operating Results

The Company projects ¥2,800.0 billion in consolidated revenue (up 10.9% year-over-year), ¥260.0 billion in operating income (up 13.2% year-over-year), ¥270.0 billion in income before income taxes (up 3.7% year-over-year) and ¥200.0 billion in net income attributable to FUJIFILM Holdings (down 5.3% year-over-year).

The projected currency exchange rates for the U.S. dollar and the euro against the yen during the fiscal year ending March 31, 2023, are ¥135 and ¥141, respectively.

The annual dividend for the fiscal year ending March 31, 2023 is expected to be ¥120 per share.

2. MATTERS RELATING TO SUMMARY (OTHER) INFORMATION

(1) Changes in Status of Material Subsidiaries during This Quarter (Company Newly Consolidated or Removed from Consolidation):

None

(2) Adoption of Simplified Method of Accounting or Specific Accounting Treatments:

None

(3) Changes in Accounting Principles:

None

3. OVERVIEW OF MATERIAL EVENTS REGARDING THE GOING CONCERN ASSUMPTION:

None

4. CONSOLIDATED FINANCIAL STATEMENTS

(1) Consolidated Balance Sheets

Amount Unit: Millions of yen

	As of December 31, 2022	As of March 31, 2022	Change
ASSETS			
Current assets:			
Cash and cash equivalents	317,839	486,328	(168,489)
Notes and accounts receivable:			
Trade	632,129	570,851	61,278
Lease receivable	41,696	45,573	(3,877)
Affiliated companies	1,896	2,354	(458)
Allowance for doubtful receivables	(19,592)	(20,144)	552
	656,129	598,634	57,495
Inventories	621,039	504,467	116,572
Prepaid expenses and Other	161,386	135,300	26,086
Total current assets	1,756,393	1,724,729	31,664
Investments and long-term receivables:			
Investments in and advances to affiliated companies	43,002	43,467	(465)
Investment securities	78,785	105,329	(26,544)
Long-term lease receivables	55,588	60,298	(4,710)
Other long-term receivables	20,589	24,963	(4,374)
Allowance for doubtful receivables	(2,731)	(3,010)	279
Total investments and long-term receivables	195,233	231,047	(35,814)
Property, plant and equipment:			
Land	105,617	104,718	899
Buildings	747,792	739,525	8,267
Machinery, equipment and other	1,506,271	1,497,457	8,814
Construction in progress	267,877	145,084	122,793
	2,627,557	2,486,784	140,773
Less accumulated depreciation	(1,740,068)	(1,749,945)	9,877
Total property, plant and equipment	887,489	736,839	150,650
Other assets:			
Operating lease right-of-use assets	85,963	83,389	2,574
Goodwill, net	842,955	824,003	18,952
Other intangible assets, net	150,237	152,691	(2,454)
Other	230,258	202,582	27,676
Total other assets	1,309,413	1,262,665	46,748
Total assets	4,148,528	3,955,280	193,248

Amount Unit: Millions of yen

	As of December 31, 2022	As of March 31, 2022	Change
LIABILITIES			
Current liabilities:			
Short-term debt	171,200	200,095	(28,895)
Notes and accounts payable:			
Trade	262,974	249,919	13,055
Construction	48,260	51,868	(3,608)
Affiliated companies	1,466	1,396	70
	312,700	303,183	9,517
Accrued income taxes	34,822	21,453	13,369
Accrued liabilities	219,465	226,830	(7,365)
Short-term operating lease liabilities	31,906	31,494	412
Other current liabilities	157,524	196,520	(38,996)
Total current liabilities	927,617	979,575	(51,958)
Long-term liabilities:			
Long-term debt	306,057	247,101	58,956
Accrued pension and severance costs	23,980	27,927	(3,947)
Long-term operating lease liabilities	58,261	56,866	1,395
Other long-term liabilities	113,670	118,871	(5,201)
Total long-term liabilities	501,968	450,765	51,203
Total liabilities	1,429,585	1,430,340	(755)
EQUITY			
FUJIFILM Holdings shareholders' equity			
Capital	40,363	40,363	-
Common stock, without par value:			
Authorized: 800,000,000 shares			
Issued: 514,625,728 shares			
Retained earnings	2,997,281	2,867,848	129,433
Accumulated other comprehensive income (loss)	137,478	75,993	61,485
Treasury stock, at cost	(480,291)	(481,547)	1,256
Total FUJIFILM Holdings shareholders' equity	2,694,831	2,502,657	192,174
Noncontrolling interests	24,112	22,283	1,829
Total equity	2,718,943	2,524,940	194,003
Total liabilities and equity	4,148,528	3,955,280	193,248

Note: Details of accumulated other comprehensive income (loss)

	As of December 31, 2022	As of March 31, 2022	Change
Unrealized gains (losses) on securities	(155)	27	(182)
Foreign currency translation adjustments	208,605	148,700	59,905
Pension liability adjustments	(71,196)	(72,780)	1,584
Unrealized gains (losses) on derivatives	224	46	178

(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
(Consolidated Statements of Income)

Nine months ended December 31

Amount Unit: Millions of yen

	Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022		Nine months ended December 31, 2021 From April 1, 2021 To December 31, 2021		Change	
					Amount	%
	%		%			
Revenue	100.0	2,094,260	100.0	1,860,902	233,358	12.5
Cost of sales	59.8	1,252,475	57.8	1,076,403	176,072	16.4
Gross profit	40.2	841,785	42.2	784,499	57,286	7.3
Operating expenses:						
Selling, general and administrative	25.0	524,210	26.2	486,105	38,105	7.8
Research and development	5.5	114,938	6.0	111,941	2,997	2.7
Operating income	30.5	639,148	32.2	598,046	41,102	6.9
Operating income	9.7	202,637	10.0	186,453	16,184	8.7
Other income (expenses):						
Interest and dividend income		5,248		4,041	1,207	
Interest expense		(2,555)		(1,663)	(892)	
Foreign exchange gains (losses), net		(3,287)		471	(3,758)	
Gains (losses) on equity securities, net		(3,432)		5,874	(9,306)	
Other, net		6,176		12,064	(5,888)	
Income before income taxes	0.1	2,150	1.1	20,787	(18,637)	(89.7)
Income before income taxes	9.8	204,787	11.1	207,240	(2,453)	(1.2)
Income taxes	2.6	53,409	3.1	57,122	(3,713)	(6.5)
Equity in net earnings (losses) of affiliated companies	0.2	3,565	0.6	10,330	(6,765)	(65.5)
Net income	7.4	154,943	8.6	160,448	(5,505)	(3.4)
Less: Net (income) loss attributable to the noncontrolling interests	(0.1)	(1,208)	(0.2)	(3,342)	2,134	(63.9)
Net income attributable to FUJIFILM Holdings	7.3	153,735	8.4	157,106	(3,371)	(2.1)

Three months ended December 31

Amount Unit: Millions of yen

	Three months ended December 31, 2022 From October 1, 2022 To December 31, 2022		Three months ended December 31, 2021 From October 1, 2021 To December 31, 2021		Change	
					Amount	%
	%		%			
Revenue	100.0	744,329	100.0	655,768	88,561	13.5
Cost of sales	59.6	443,258	57.6	377,622	65,636	17.4
Gross profit	40.4	301,071	42.4	278,146	22,925	8.2
Operating expenses:						
Selling, general and administrative	24.2	180,813	24.9	163,391	17,422	10.7
Research and development	5.2	38,431	5.5	36,164	2,267	6.3
Operating income	29.4	219,244	30.4	199,555	19,689	9.9
Operating income	11.0	81,827	12.0	78,591	3,236	4.1
Other income (expenses):						
Interest and dividend income		2,241		1,595	646	
Interest expense		(752)		(570)	(182)	
Foreign exchange gains (losses), net		(7,618)		1,324	(8,942)	
Gains (losses) on equity securities, net		(2,922)		(8,007)	5,085	
Other, net		2,477		4,406	(1,929)	
Income before income taxes	(0.9)	(6,574)	(0.2)	(1,252)	(5,322)	425.1
Income before income taxes	10.1	75,253	11.8	77,339	(2,086)	(2.7)
Income taxes	2.5	18,425	3.2	20,887	(2,462)	(11.8)
Equity in net earnings of affiliated companies	0.2	1,480	0.9	5,616	(4,136)	(73.6)
Net income	7.8	58,308	9.5	62,068	(3,760)	(6.1)
Less: Net (income) loss attributable to the noncontrolling interests	0.1	264	(0.2)	(1,220)	1,484	(121.6)
Net income attributable to FUJIFILM Holdings	7.9	58,572	9.3	60,848	(2,276)	(3.7)

(Consolidated Statements of Comprehensive Income)**Nine months ended December 31**

Amount Unit: Millions of yen

	Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022	Nine months ended December 31, 2021 From April 1, 2021 To December 31, 2021	Change
Net income	154,943	160,448	(5,505)
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	(182)	6	(188)
Foreign currency translation adjustments	60,858	39,736	21,122
Pension liability adjustments	1,554	1,982	(428)
Unrealized gains (losses) on derivatives	178	(140)	318
Total	62,408	41,584	20,824
Comprehensive income	217,351	202,032	15,319
Less: Comprehensive income attributable to noncontrolling interests	(2,131)	(3,964)	1,833
Comprehensive income (loss) attributable to FUJIFILM Holdings	215,220	198,068	17,152

Three months ended December 31

Amount Unit: Millions of yen

	Three months ended December 31, 2022 From October 1, 2022 To December 31, 2022	Three months ended December 31, 2021 From October 1, 2021 To December 31, 2021	Change
Net income	58,308	62,068	(3,760)
Other comprehensive income (loss), net of tax:			
Unrealized gains (losses) on securities	(258)	2	(260)
Foreign currency translation adjustments	(90,034)	32,951	(122,985)
Pension liability adjustments	497	687	(190)
Unrealized gains (losses) on derivatives	143	28	115
Total	(89,652)	33,668	(123,320)
Comprehensive income	(31,344)	95,736	(127,080)
Less: Comprehensive income attributable to noncontrolling interests	1,810	(1,781)	3,591
Comprehensive income (loss) attributable to FUJIFILM Holdings	(29,534)	93,955	(123,489)

(3) Consolidated Statements of Cash Flows

Amount Unit: Millions of yen

	Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022	Nine months ended December 31, 2021 From April 1, 2021 To December 31, 2021	Change
Operating activities			
Net income	154,943	160,448	(5,505)
Adjustments to reconcile net income to net cash provided by operating activities:			
Depreciation and amortization	106,734	97,740	8,994
(Gains) losses on equity securities, net	3,432	(5,874)	9,306
Equity in net (gains) losses of affiliated companies, net of dividends received	(2,960)	(9,959)	6,999
Changes in operating assets and liabilities:			
Notes and accounts receivable	(46,773)	35,359	(82,132)
Inventories	(108,312)	(66,141)	(42,171)
Notes and accounts payable - trade	9,507	7,881	1,626
Changes in other current assets	(16,576)	(13,836)	(2,740)
Accrued income taxes and other liabilities	(29,443)	1,549	(30,992)
Other	(7,322)	6,312	(13,634)
Subtotal	(91,713)	53,031	(144,744)
Net cash provided by operating activities	63,230	213,479	(150,249)
Investing activities			
Purchases of property, plant and equipment	(191,004)	(90,858)	(100,146)
Purchases of software	(35,638)	(26,961)	(8,677)
Proceeds from sales and maturities of marketable and investment securities	28,006	11,925	16,081
Purchases of marketable and investment securities	(3,316)	(2,211)	(1,105)
(Increase) decrease in time deposits, net	(3,855)	(2,316)	(1,539)
Increase in investments in and advances to affiliated companies	(512)	(454)	(58)
Acquisitions of businesses, net of cash acquired	(15,428)	1,291	(16,719)
Other	(4,232)	(5,650)	1,418
Net cash used in investing activities	(225,979)	(115,234)	(110,745)
Financing activities			
Proceeds from long-term debt	120,164	2,362	117,802
Repayments of long-term debt	(91,684)	(31,340)	(60,344)
Increase (decrease) in short-term debt with maturities of three months or less, net	(639)	(1,900)	1,261
Cash dividends paid to shareholders	(46,109)	(43,032)	(3,077)
Subsidiaries' cash dividends paid to noncontrolling interests	(372)	(777)	405
Net purchases of stock for treasury	(18)	(24)	6
Capital transactions with noncontrolling interests and other	(2,640)	(3,162)	522
Net cash used in financing activities	(21,298)	(77,873)	56,575
Effect of exchange rate changes on cash and cash equivalents	15,558	9,881	5,677
Net increase (decrease) in cash and cash equivalents	(168,489)	30,253	(198,742)
Cash and cash equivalents at beginning of period	486,328	394,795	91,533
Cash and cash equivalents at end of period	317,839	425,048	(107,209)

(4) Notes to Consolidated Financial Statements

Note Relating to the Going Concern Assumption

N/A

Segment Information

1. Nine months ended December 31

(A) Operating Segment Information

a. Revenue

Amount Unit: Millions of yen

	Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022		Nine months ended December 31, 2021 From April 1, 2021 To December 31, 2021		Change	
	%		%		Amount	%
Revenue:						
Healthcare:						
External customers	30.2	633,777	31.0	576,728	57,049	9.9
Intersegment		48		58	(10)	-
Total		633,825		576,786	57,039	9.9
Materials:						
External customers	25.0	522,655	25.1	467,348	55,307	11.8
Intersegment		913		974	(61)	-
Total		523,568		468,322	55,246	11.8
Business Innovation:						
External customers	29.3	614,079	29.9	556,661	57,418	10.3
Intersegment		6,768		2,929	3,839	-
Total		620,847		559,590	61,257	10.9
Imaging:						
External customers	15.5	323,749	14.0	260,165	63,584	24.4
Intersegment		1,967		1,710	257	-
Total		325,716		261,875	63,841	24.4
Eliminations		(9,696)		(5,671)	(4,025)	-
Consolidated total	100.0	2,094,260	100.0	1,860,902	233,358	12.5

b. Operating income

Amount Unit: Millions of yen

	Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022		Nine months ended December 31, 2021 From April 1, 2021 To December 31, 2021		Change	
	%		%		Amount	%
Operating Income:						
Healthcare	9.6	60,627	13.1	75,317	(14,690)	(19.5)
Materials	11.4	59,519	12.4	58,198	1,321	2.3
Business Innovation	7.7	47,793	7.5	41,855	5,938	14.2
Imaging	19.3	62,732	13.3	34,703	28,029	80.8
Total		230,671		210,073	20,598	9.8
Corporate expenses and eliminations		(28,034)		(23,620)	(4,414)	-
Consolidated total	9.7	202,637	10.0	186,453	16,184	8.7

Note: The major products and services of each operating segment are as follows:

Healthcare:	Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, iPS cells (regenerative medicine), drug discovery support such as cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
Materials:	Electronic materials, display materials, industrial equipment, fine chemicals, recording media, equipment and materials for graphic communication, inks and industrial inkjet printheads, etc.
Business Innovation:	Digital MFPs, solutions and services, etc.
Imaging:	Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

c. Overseas revenue (Destination Base)

Amount Unit: Millions of yen

	Nine months ended December 31, 2022 From April 1, 2022 To December 31, 2022		Nine months ended December 31, 2021 From April 1, 2021 To December 31, 2021		Change	
					Amount	%
Revenue:	%		%			
Domestic	34.5	722,759	38.2	710,401	12,358	1.7
Overseas:						
The Americas	23.3	488,110	21.2	394,912	93,198	23.6
Europe	15.2	318,014	13.3	248,243	69,771	28.1
Asia and others	27.0	565,377	27.3	507,346	58,031	11.4
Subtotal	65.5	1,371,501	61.8	1,150,501	221,000	19.2
Consolidated total	100.0	2,094,260	100.0	1,860,902	233,358	12.5

Note: The presentation of the overseas revenue (Destination Base) has been classified and disclosed based on the customer's location.

2. Three months ended December 31

(A) Revenue by Operating Segment

Amount Unit: Millions of yen

	Three months ended December 31, 2022 From October 1, 2022 To December 31, 2022		Three months ended December 31, 2021 From October 1, 2021 To December 31, 2021		Change	
					Amount	%
Revenue:	%		%			
Healthcare	29.2	217,655	30.6	201,136	16,519	8.2
Materials	22.9	170,674	24.3	159,493	11,181	7.0
Business Innovation	29.0	215,656	28.0	183,287	32,369	17.7
Imaging	18.9	140,344	17.1	111,852	28,492	25.5
Consolidated total	100.0	744,329	100.0	655,768	88,561	13.5

Note: The major products and services of each operating segment are as follows:

- Healthcare: Equipment and materials for medical systems, contract development and manufacturing organization of biopharmaceuticals, iPS cells (regenerative medicine), drug discovery support such as cell culture media and reagents, pharmaceuticals, cosmetics and supplements, etc.
- Materials: Electronic materials, display materials, industrial equipment, fine chemicals, recording media, equipment and materials for graphic communication, inks and industrial inkjet printheads, etc.
- Business Innovation: Digital MFPs, solutions and services, etc.
- Imaging: Instant photo systems, color films, services and equipment for photofinishing, digital cameras and optical devices, etc.

(B) Overseas Revenue (Destination Base)

Amount Unit: Millions of yen

	Three months ended December 31, 2022 From October 1, 2022 To December 31, 2022		Three months ended December 31, 2021 From October 1, 2021 To December 31, 2021		Change	
					Amount	%
Revenue:	%		%			
Domestic	32.8	244,186	36.5	239,115	5,071	2.1
Overseas:						
The Americas	24.5	182,724	22.0	144,290	38,434	26.6
Europe	15.9	118,372	14.4	94,666	23,706	25.0
Asia and others	26.8	199,047	27.1	177,697	21,350	12.0
Subtotal	67.2	500,143	63.5	416,653	83,490	20.0
Consolidated total	100.0	744,329	100.0	655,768	88,561	13.5

Note on Significant Changes to FUJIFILM Holdings Shareholders' Equity

N/A

(Subsequent Event)

Cancellation of Treasury Shares

The Company resolved to cancel treasury shares as shown below pursuant to Article 178 of the Companies Act.

1. Class of shares to be cancelled: The Company's common stock
2. Total number of shares to be cancelled: 100,000,000 shares (19.4% of the total number of issued shares outstanding before cancellation)
3. Date of cancellation: February 28, 2023

(Reference)

Total number of issued shares outstanding after cancellation: 414,625,728 shares

Number of treasury shares after cancellation: 13,535,858 shares

(The above number of treasury shares is calculated based on the number of treasury shares as of December 31, 2022)